Home » Topics » BioWorld Science

BioWorld Science
RSS

First subject dosed in phase I study of SM-07883

April 5, 2019

Entasis Therapeutics initiates global phase III ATTACK study of ETX-2514SUL

April 5, 2019

Amgen identifies KRAS mutant inhibitors

April 5, 2019

Fate Therapeutics gives update on phase I study of FT-500

April 5, 2019

Phase I results of highly selective dual IDO1/TDO2 inhibitor M-4112 in advanced solid malignancies

April 4, 2019

Comparison of the novel biguanide NT-1195 with metformin/phenformin in endometrial cancer models

April 4, 2019

Preclinical results of EI-1071, a selective CSF1R inhibitor regulating tumor-associated macrophages

April 4, 2019

Bluevalley Pharmaceutical discloses ATR inhibitors

April 4, 2019

U.S. researchers synthesize antisense oligonucleotides targeting MYC

April 4, 2019

TNFRSF18-targeting shRNAs described in Shenzhen Biocan Technologies patent

April 4, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Taiwan biotech looks outward in next phase of growth
BioWorld
Taiwan’s biotechnology sector was built around domestic health needs, including vaccines and drug manufacturing, but it is increasingly looking outward – to...